Go to Bing homepage
Go to Bing homepage

In particular, the FDA approval of Luxturna, a new gene therapy for the treatment of children and adult patients with an inherited form of vision loss that may …
Zacks Investment Research · 10d
controlled trial ever completed in gene therapy for a genetic disease. Medical history was made once again when a 13-year-old boy with an RPE65 …
Healio · 3d
Pricing for gene therapy/editing is likely underestimated. As more treatments like Spark's Luxturna get priced, it will become evident that the total …
Seeking Alpha · 3d
AAV technology forms the basis of many of the gene therapies currently in development, as well as the first to receive Food and Drug Administration approval, …
MedCity News · 11d
Interestingly, Luxturna of Spark Therapeutics (NASDAQ:ONCE), the first FDA-approved gene therapy to treat a rare retinal disease also employs AAV. As the most promising subsidiary of Fortress Biotech, Mustang is …
Seeking Alpha · 3d
To target and restore the expression in RPE65, Spark Therapeutics has developed a gene therapy known as Luxturna, which uses genetic …
pharmaphorum · 5d
Spark in December received Food and Drug Administration approval for Luxturna, a one-time gene therapy treatment for patients with an inherited …
The Business Journals · 6d
We remind investors that Spark, in December 2017, obtained the FDA approval for its lead gene therapy drug, Luxturna (voretigene neparvovec-rzyl), …
Zacks Investment Research · 5d
He has overseen investigational product chemistry, manufacturing and controls for gene therapy viral vectors for more than 200 human subjects in 12 clinical programs, including LUXTURNA, the first gene therapy approved …
PharmiWeb · 9d